Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.5K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.5K
Hormonal Regulation01:40

Hormonal Regulation

49.0K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
49.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

979
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
979
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

1.7K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.7K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spaced training improves learning in Ts65Dn and Ube3a mouse models of intellectual disabilities.

Translational psychiatry·2019
Same author

Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities.

Genes, brain, and behavior·2017
Same author

Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders.

Molecular psychiatry·2017
Same author

Behavioral phenotypes of genetic mouse models of autism.

Genes, brain, and behavior·2015
Same author

GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2015
Same author

3D visualization of the regional differences.

Molecular psychiatry·2015
Same journal

Structural pharmacology of TRPA1 channel.

Trends in pharmacological sciences·2026
Same journal

Recent advances in venom pharmacology reshaping venom-to-drug discovery.

Trends in pharmacological sciences·2026
Same journal

Engineering cells for solid tumor therapy.

Trends in pharmacological sciences·2026
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Cholecystokinin-dopamine interactions.

J N Crawley1

  • 1Unit on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD 20892.

Trends in Pharmacological Sciences
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

Cholecystokinin (CCK) excites and modulates dopamine's inhibitory actions in the brain. New receptor antagonists offer tools to study CCK's role in dopamine function and potential treatments for neuropsychiatric disorders.

More Related Videos

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.2K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.9K

Related Experiment Videos

Last Updated: Feb 28, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.2K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.9K

Area of Science:

  • Neuroscience
  • Neuropharmacology

Background:

  • Cholecystokinin (CCK) is found alongside dopamine in key brain areas like the ventral tegmental area and substantia nigra.
  • This coexistence suggests a potential interaction between CCK and dopamine systems in the brain.

Purpose of the Study:

  • To review neurophysiological, behavioral, and release studies on CCK's role in the mesolimbic pathway.
  • To explore the potential of CCK receptor antagonists in understanding CCK's modulation of dopaminergic function.
  • To assess the therapeutic potential of CCK-based drugs for neuropsychiatric disorders.

Main Methods:

  • Integration of existing neurophysiological data.
  • Analysis of behavioral studies related to CCK and dopamine.
  • Review of studies on CCK release mechanisms.
  • Examination of data from studies using selective CCKA and CCKB receptor antagonists.

Main Results:

  • CCK exhibits excitatory effects within the mesolimbic pathway.
  • CCK facilitates and modulates the inhibitory actions of dopamine.
  • Selective nonpeptide CCKA and CCKB receptor antagonists are now available.

Conclusions:

  • Endogenous CCK plays a significant role in modulating dopaminergic function.
  • CCK receptor antagonists are valuable tools for investigating these modulatory roles.
  • CCK-based drugs show promise for treating neuropsychiatric disorders.